| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 09/26/2002 | WO2001090143A3 Polypeptides containing polymorphisms of the repeated regions of pertactin in bordetella pertussis, bordetella parapertussis and bordetella bronchiseptica. their use in diagnostics, and in immunogenic compositions |
| 09/26/2002 | WO2001083775A3 Proteases |
| 09/26/2002 | WO2001047953A3 Antibodies against plasma cells |
| 09/26/2002 | WO2001019861A9 Apo-2 receptor antibodies |
| 09/26/2002 | WO2001018550A9 Determination of adrenomedullin-binding proteins |
| 09/26/2002 | WO2000074634A9 Methods and compositions for modulating cell proliferation and cell death |
| 09/26/2002 | WO2000027868A9 Connective tissue growth factor (ctgf) and methods of use |
| 09/26/2002 | US20020138872 Transgenic plants; enhanced defense mechanisms to combat plant diseases; disease resistant plants |
| 09/26/2002 | US20020138860 Novel uses of mammalian CCR6 receptors and related reagents |
| 09/26/2002 | US20020138857 Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
| 09/26/2002 | US20020138207 Flexible processing apparatus for isolating and purifying viruses, soluble proteins and peptides from plant sources |
| 09/26/2002 | US20020137910 MN gene and protein |
| 09/26/2002 | US20020137909 Designated as "PRO19598" polypeptides; diagnosis and treatment of tumors |
| 09/26/2002 | US20020137899 Crosslinked through one or more carbohydrate moieties in said glycoprotein; storage stability, chemical stability over wider range of conditions while retaining bioactivity in use |
| 09/26/2002 | US20020137897 Optimizing production of recombinant antibodies and nucleic acid sequences which code for novel light chain proteins, by substitution of interfacial amino acids |
| 09/26/2002 | US20020137891 Inserting a nucleic acid sequence encoding a heterologous polypeptide into a nucleic acid sequence encoding subunit of an oligomerisable protein scaffold, incorporating it into expression vector to express nucleic acid to produce monomer |
| 09/26/2002 | US20020137885 Corticotropin release inhibiting factor and methods of using same |
| 09/26/2002 | US20020137697 Chimeric receptor genes and cells transformed therewith |
| 09/26/2002 | US20020137202 Diagnosis, treatment, and prevention of disorders associated with a FCTRX nucleic acid, polypeptide, or an antibody specific for it |
| 09/26/2002 | US20020137184 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and use thereof |
| 09/26/2002 | US20020137182 For obtaining and using a polypeptide other than oncogene BCL-2 that affects programmed vertebrate cell death |
| 09/26/2002 | US20020137173 Prepared by homogenizing bovine brain tissue, centrifuging homogenate to remove cell debris and nuclei, treating the cell membrane debris pellet with ammonium sulfate, treating using chromatography, centrifuging |
| 09/26/2002 | US20020137171 Nucleic acid encoding a polypeptide having hydrolase activity |
| 09/26/2002 | US20020137170 Dual-specificity protein tyrosine phosphatases that dephosphorylate both phosphotyrosine and phosphothreonine/serine residues |
| 09/26/2002 | US20020137166 ASIP-related proteins |
| 09/26/2002 | US20020137142 Tango-73 nucleic acids |
| 09/26/2002 | US20020137138 Modulating serotonin activity |
| 09/26/2002 | US20020137137 Genetic engineering; polypeptides |
| 09/26/2002 | US20020137133 Receptor proteins |
| 09/26/2002 | US20020137129 Polypeptides; genetic engineering; drug development |
| 09/26/2002 | US20020137127 Culture product; polypeptides |
| 09/26/2002 | US20020137119 Immunoassay; quantitative analysis |
| 09/26/2002 | US20020137113 Kinase receptor activation assay |
| 09/26/2002 | US20020137112 Monitoring using adduct of amyloid protein modified with malonaldehyde |
| 09/26/2002 | US20020137110 Detecting apoptosis |
| 09/26/2002 | US20020137109 Anticarcinogenic agents;monitoring therapy efficiency |
| 09/26/2002 | US20020137092 Peptide derived from an antigen recognized by autoantibodies from patients with rheumatoid arthritis, antibody directed against said peptide, a combinatorial antigen, and a method of detecting auto- immune antibodies |
| 09/26/2002 | US20020137044 Novel nucleic acids and polypeptides |
| 09/26/2002 | US20020137038 Intestinal proteins |
| 09/26/2002 | US20020137028 Use of neuronal apoptosis inhibitor protein (naip) |
| 09/26/2002 | US20020137019 Method for screening transcriptional coregulatory proteins of transcription factors, and androgen receptor transcriptional coregulatory proteins as targets for androgen receptor-dependent diseases |
| 09/26/2002 | US20020136754 Recombinant bacterial phytases and uses thereof |
| 09/26/2002 | US20020136741 Extracting with a polyoxyethylene detergent to deplete inner membranes, extracting remaining outer membranes with zwitterionic betaine dertergent to separate lipooligosaccharides from insoluble factions used for vaccines |
| 09/26/2002 | US20020136730 From coagulase-negative bacteria produced in substantially pure form; use of purified adhesin product as vaccine for production of antibodies effective against binding of homologous bacterial cells to polymeric materials |
| 09/26/2002 | US20020136729 Combined physical and immunotherapy for cancer |
| 09/26/2002 | US20020136727 Immunogen adherence inhibitor and method of making and using same |
| 09/26/2002 | US20020136723 Administering methotrexate and an anti-tumor necrosis factor antibody or fragment thereof; rheumatoid arthritis, Crohn's disease, acute and chronic immune diseases |
| 09/26/2002 | US20020136722 Adjuvants comprising CD40 ligands crosslinked to antigens, wherein the adjuvants have reduced toxicity and adjuvants comprising CD40 ligands crosslinked to viral antigens |
| 09/26/2002 | US20020136721 Specifically binds to hepatocyte growth factor receptor; for treating cancer |
| 09/26/2002 | US20020136719 For biomedical applications, including biological delivery to humans and animals |
| 09/26/2002 | US20020136718 Using antibody which catalyzes hydrolysis of beta-amyloid at a predetermined amide linkage |
| 09/26/2002 | US20020136717 Process for screening chemical compounds for modulating the interaction of an EVH1 domain or a protein having an EVH1 domain with an EVH1 binding domain or a protein having an EVH1 binding domain, and a process for detecting said interaction |
| 09/26/2002 | US20020136715 Composition comprising a binding agent that specifically binds to circulating prostate specific antigen and induces a therapeutic immune response |
| 09/26/2002 | US20020136713 Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV |
| 09/26/2002 | US20020136695 Human medical treatment by aerosol inhalation of immunoglobulin A |
| 09/26/2002 | US20020136689 Antibody which specifically binds to prostate stem cell antigen on surface of carcinoma cells and is internalized within carcinoma cells to which it binds |
| 09/26/2002 | CA2852293A1 Attenuated pasteurellaceae bacteria and an anti-bacterial vaccine prepared therefrom |
| 09/26/2002 | CA2441902A1 Chimpanzee erythropoietin (chepo) - immunoadhesins |
| 09/26/2002 | CA2441510A1 Muteins of hypoxia inducible factor alpha and methods of use thereof |
| 09/26/2002 | CA2441057A1 Polyclonal populations of bispecific molecules and methods of production and uses thereof |
| 09/26/2002 | CA2441042A1 Monoclonal antibody therapy for pancreas cancer |
| 09/26/2002 | CA2440960A1 An early pre-symptomatic prion diagnostic blood test for encephalopathies |
| 09/26/2002 | CA2440859A1 Transgenic animal model of ige-mediated allergic responses |
| 09/26/2002 | CA2440272A1 Nucleic acid-associated proteins |
| 09/26/2002 | CA2440028A1 Rearranged squamous cell carcinoma antigen genes ii |
| 09/26/2002 | CA2439530A1 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
| 09/26/2002 | CA2438483A1 Histidine phosphatase interacting protein with 240kd |
| 09/26/2002 | CA2438315A1 Attenuated pasteurellaceae bacteria and an anti-bacterial vaccine prepared therefrom |
| 09/26/2002 | CA2425902A1 Urocortin-iii and uses thereof |
| 09/25/2002 | EP1243652A2 Glial derived neurotrophic factor |
| 09/25/2002 | EP1243650A2 Process for constructing a cdna library, and a polypeptide and dna coding for the same |
| 09/25/2002 | EP1243597A2 Receptors for human interleukin-12 |
| 09/25/2002 | EP1242823A2 Selecting library members capable of binding to epitopes |
| 09/25/2002 | EP1242617A2 Method of classifying a thyroid carcinoma using differential gene expression |
| 09/25/2002 | EP1242606A2 Schizophrenia associated gene, proteins and biallelic markers |
| 09/25/2002 | EP1242601A1 Trichoderma reesei xylanase |
| 09/25/2002 | EP1242600A1 Cytokine zcyto18 |
| 09/25/2002 | EP1242596A1 Methods and materials relating to novel von willebrand/thrombospondin-like polypeptides and polynucleotides |
| 09/25/2002 | EP1242590A2 Human lyases and associated proteins |
| 09/25/2002 | EP1242584A2 Human kinases |
| 09/25/2002 | EP1242583A2 Human oxidoreductase proteins |
| 09/25/2002 | EP1242580A1 Methods and materials relating to semaphorin-like polypeptides and polynucleotides |
| 09/25/2002 | EP1242460A2 Immobilisation of proteins using a polypeptide segment |
| 09/25/2002 | EP1242459A1 Methods and compositions for determining the purity of chemically synthesized nucleic acids |
| 09/25/2002 | EP1242458A2 Brain specific binding members |
| 09/25/2002 | EP1242457A1 Intrabodies with defined framework that is stable in a reducing environment and applications thereof |
| 09/25/2002 | EP1242456A2 Scfv antibodies against disease associated molecules |
| 09/25/2002 | EP1242446A1 Immunoenzymatic quantification method |
| 09/25/2002 | EP1242401A1 Cytotoxic agents comprising taxanes and their therapeutic use |
| 09/25/2002 | EP1242122A2 Delivery of proteins across polar epithelial cell layers |
| 09/25/2002 | EP1242060A1 Treatment of metastatic disease |
| 09/25/2002 | EP1159000B1 Preparation for the treatment of pigmentation disorders |
| 09/25/2002 | EP1060184A4 Best's macular dystrophy gene |
| 09/25/2002 | EP0981549B1 Use of an inhibitor substance for the improvement of neuronal regeneration |
| 09/25/2002 | EP0975971A4 Methods for detecting cell apoptosis |
| 09/25/2002 | EP0975765A4 Plant fatty acid epoxygenase genes and uses therefor |
| 09/25/2002 | EP0972020B1 Insulin-like growth factor agonist molecules |
| 09/25/2002 | EP0804591B1 Serum paraoxonase |
| 09/25/2002 | EP0696320B1 Human n-methyl-d-aspartate receptor subunits, nucleic acids encoding same and uses therefor |
| 09/25/2002 | CN1371421A Tankyrase 2 materials and methods |